FRET-Based Assay for Amyloid Seeding Quantification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for quantifying the seeding activity of amyloidogenic aggregates, such as those involved in Huntington's disease, are limited by insensitivity in complex biosamples and the need for upstream purification of seeds.
Innovation Solution
A FRET-based assay using fluorophore-tagged amyloidogenic proteins allows for the sensitive quantification of seeding activity in complex biosamples without the need for upstream purification, by measuring the time at half-maximal FRET efficiency (Δt50) in the presence and absence of amyloidogenic protein aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If Thioflavin T-based assays are used to monitor seed-mediated amyloid polymerization, then amyloid formation can be detected, but sensitivity is insufficient in complex biosamples and upstream purification of seeds is required
Solution Approach 1:
The patent uses fluorescently tagged amyloidogenic proteins (e.g., CFP-tagged and YFP-tagged huntingtin proteins) as intermediary reporter molecules that mediate the detection of seeding activity. These tagged proteins serve as substrates that interact with the seeds in the biosample, and their aggregation state is reported through FRET signals, eliminating the need for direct detection of the seeds themselves and thus removing the purification requirement while enhancing sensitivity
Solution Approach 2:
The patent changes the detection parameter from Thioflavin T fluorescence (which has insufficient sensitivity in complex matrices) to FRET efficiency measurements between donor (CFP) and acceptor (YFP) fluorophores. This parameter change enables detection of subtle aggregation changes in complex biosamples without purification, as FRET signals provide higher sensitivity and can distinguish specific aggregation events from background noise
2Reliability
If conventional amyloid assays are used, then amyloid formation can be monitored, but the ability to specifically detect seeding activity in complex biosamples is limited
Solution Approach 1:
Fluorescently tagged amyloidogenic proteins serve as specific intermediaries that selectively interact with seeding-competent aggregates in the biosample. The tagged proteins act as biosensors that only respond to relevant seeds through specific protein-protein interactions, ensuring high specificity while the FRET-based readout provides enhanced detection capability in complex matrices
Solution Approach 2:
The patent utilizes FRET-induced color/fluorescence changes as a specific indicator of seeding activity. When the donor (CFP) and acceptor (YFP) fluorophores are in close proximity due to protein aggregation induced by seeds, energy transfer occurs resulting in characteristic fluorescence signal changes. This optical signal change provides specific and sensitive detection of seeding activity even in complex biosamples without purification
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The FRET-based assay achieves high sensitivity and specificity in detecting seeding activity of amyloidogenic proteins like mHTT in complex biosamples, enabling effective assessment of disease risk, progression, and the identification of compounds inhibiting seeding activity.
Implementation Method 1
wherein the donor fluorophore molecule and the acceptor fluorophore molecule are capable of Förster Resonance Energy Transfer (FRET) if they are in close proximity to each other
Implementation Method 2
measuring fluorescence signals in the donor, e.g. cyan, channel, the acceptor, e.g. yellow, channel and the Förster Resonance Energy Transfer (FRET) channel
Data Source
AI summary
The present invention relates to a method for the quantification of seeding (Δt50) of an amyloidogenic aggregate, methods for assessing the risk for development, predicting the onset or assessing the progression of a polyQ disease, and a method for identifying compounds that inhibit mHTT seeding activity (HSA) in vitro. Further, uses of fluorophore-bearing polyQ proteins, particularly mutant N-terminal huntingtin fragments comprising exon-1 and related soluble protein constructs are provided.